Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

This study has been completed.
Information provided by (Responsible Party):
MedImmune LLC Identifier:
First received: November 9, 2010
Last updated: September 16, 2014
Last verified: September 2014
The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.

Condition Intervention Phase
Drug: MEDI-563
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 [ Time Frame: 12-15 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Evaluate the safety and tolerability of MEDI-563 [ Time Frame: 12-15 months ] [ Designated as safety issue: Yes ]
    • To evaluate the safety and tolerability of MEDI-563.
    • To determine the optimal dose of MEDI-563 to be used in Phase 3 studies.
    • To describe the immunogenicity (IM) and pharmacokinetics (PK) of MEDI-563.
    • To assess the effect of MEDI-563 on other assessments of clinical activity (i.e, asthma control and pulmonary function).
    • To assess the effect of MEDI-563 on health-related quality of life.

Enrollment: 965
Study Start Date: December 2010
Study Completion Date: August 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MEDI-563 - Arm A Drug: MEDI-563
Subcutaneous repeating dose
Experimental: MEDI-563 - Arm B Drug: MEDI-563
Subcutaneous repeating dose
Experimental: MEDI-563 - Arm C Drug: MEDI-563
Subcutaneous repeating dose
Placebo Comparator: Placebo Drug: Placebo
Subcutaneous repeating dose


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 through 75 years at the time of screening.
  • Adequate contraception from screening through end of trial.
  • Weight of > 45 kg but ≤ 150 kg (> 100 lb but ≤ 330 lb).
  • History of physician-diagnosed asthma for at least 12 months prior to screening.
  • Physician prescribed daily use of medium-dose or high-dose ICS plus LABA for at least 12 months prior to screening.
  • Willingness to switch to an ICS/LABA combination product.
  • Dose of other asthma controller medications must be stable for at least 30 days prior to screening.
  • At least 2 documented asthma exacerbations in the 12 months prior to screening that required use of a systemic corticosteroid burst.
  • For subjects 65 years of age or older, a chest x-ray (CXR) or chest computed tomography (CT) that is normal for an asthmatic population.
  • Ability and willingness to complete the study to Week 66, and if needed to Week 92.

Exclusion Criteria:

  • Known history of allergy or reaction to any component of the investigational product formulation.
  • History of anaphylaxis to any biologic therapy.
  • Unexplained diarrhea within 30 days prior to screening or diagnosis of helminth parasitic infestation within 6 months prior to screening.
  • Use of immunosuppressive medication within 3 months prior to screening. Chronic oral prednisone or equivalent up to 10 mg daily or 20 mg every other day for asthma is allowed.
  • Oral corticosteroid burst or short-acting systemic corticosteroid within 30 days prior to screening or during the screening/run-in period.
  • Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 30 days prior to the screening or during the screening/run-in period.
  • Receipt of immunoglobulin or blood products within 30 days prior to screening.
  • Receipt of any marketed or investigational biologic within 4 months or 5 half-lives prior to screening, whichever is longer.
  • Receipt of any investigational nonbiologic within 30 days or 5 half-lives prior to screening, whichever is longer.
  • Previously received MEDI-563.
  • Any clinically relevant abnormal findings in physical examination.
  • Past history of clinically significant cardiac disease or any electrocardiogram (ECG) abnormality.
  • Breastfeeding or lactating women.
  • History of alcohol or drug abuse within 12 months prior to screening.
  • History of any known primary immunodeficiency disorder.
  • Positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll.
  • A positive human immunodeficiency virus (HIV) test or subject taking antiretroviral medications.
  • History of cigarette smoking ≥ 10 pack-years or smoking within 12 months prior to screening.
  • Known exposure to inhaled occupational agents or fumes with an established diagnosis of occupational asthma.
  • History of cancer, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy ≥ 12 months prior to screening or other malignancies treated with apparent success with curative therapy ≥ 5 years prior to screening.
  • Stable dose of allergy vaccination regimen for less than 30 days prior to screening.
  • Subjects unable to demonstrate acceptable inhaler and peak flow meter techniques.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01238861

  Hide Study Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, California
Research Site
Los Angeles, California, United States
Research Site
Orange, California, United States
Research Site
San Diego, California, United States
Research Site
Stockton, California, United States
United States, Colorado
Research Site
Colarado Springs, Colorado, United States
Research Site
Denver, Colorado, United States
United States, Connecticut
Research Site
Waterbury, Connecticut, United States
United States, Florida
Research Site
Kissimmee, Florida, United States
Research Site
Tampa, Florida, United States
United States, Georgia
Research Site
Stockbridge, Georgia, United States
United States, Illinois
Research Site
Normal, Illinois, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
United States, Minnesota
Research Site
Rochester, Minnesota, United States
United States, Missouri
Research Site
St Louis, Missouri, United States
Research Site
St. Louis, Missouri, United States
United States, Nebraska
Research Site
Bellevue, Nebraska, United States
United States, New Jersey
Research Site
Summit, New Jersey, United States
United States, New York
Research Site
Rochester, New York, United States
United States, North Carolina
Research Site
Winston-Salem, North Carolina, United States
United States, Ohio
Research Site
Cincinnati, Ohio, United States
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Research Site
Blue Bell, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Research Site
Warwick, Rhode Island, United States
United States, Texas
Research Site
Boerne, Texas, United States
Research Site
San Antonio, Texas, United States
United States, Washington
Research Site
Seattle, Washington, United States
Research Site
Caba, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Santa Fe, Argentina
Research Site
Tucumán, Argentina
Research Site
Curitiba, Brazil
Research Site
Florianópolis, Brazil
Research Site
Juiz de Fora, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
Santo André, Brazil
Research Site
Sao Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Pleven, Bulgaria
Research Site
Ruse, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Troyan, Bulgaria
Canada, Ontario
Research Site
Brampton, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Canada, Quebec
Research Site
La Malbaie, Quebec, Canada
Research Site
Quebec, Canada
Research Site
Bogota, Colombia
Research Site
Bogotá, Colombia
Research Site
Guadalajara, Mexico
Research Site
Mexico, Mexico
Research Site
Monterrey, Mexico
Research Site
Morelia, Mexico
Research Site
Villahermosa, Mexico
Research Site
Zapopan, Mexico
Research Site
Lima, Peru
Research Site
San Borja, Peru
Research Site
San Isidro, Peru
Research Site
Surco, Peru
Research Site
Białystok, Poland
Research Site
Bydgoszcz, Poland
Research Site
Lublin, Poland
Research Site
Ostrów Wielkopolski, Poland
Research Site
Pila, Poland
Research Site
Poznań, Poland
Research Site
Tarnów, Poland
Research Site
Warszawa, Poland
Research Site
Łódź, Poland
Russian Federation
Research Site
Barnaul, Russian Federation
Research Site
Chelyabinsk, Russian Federation
Research Site
Ekaterinburg, Russian Federation
Research Site
Kazan, Russian Federation
Research Site
Moscow, Russian Federation
Research Site
Novosibirsk, Russian Federation
Research Site
Saint Petersburg, Russian Federation
Research Site
Saint-Petersburg, Russian Federation
Research Site
St-Petersburg, Russian Federation
Sponsors and Collaborators
MedImmune LLC
Study Director: Donald Raible, MD MedImmune LLC
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: MedImmune LLC Identifier: NCT01238861     History of Changes
Other Study ID Numbers: MI-CP220  2010-020126-17 
Study First Received: November 9, 2010
Last Updated: September 16, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by MedImmune LLC:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on October 21, 2016